Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FEM Perimeno
- Development stage
- Unknown
- Lead developer
- UPSA
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
FEM Perimeno is a non-hormonal dietary supplement formulated to support physical and emotional changes associated with perimenopause, such as hot flashes, night sweats, fatigue, sleep disturbances, and mood swings. Developed under the FEM by UPSA brand, the product combines PeriCyTonin (also known as Pure CyTonin), a purified, non-estrogenic cytoplasmic Swedish pollen extract, with saffron extract and vitamin E. The pollen-extract technology is developed by Sérélys Pharma, which was acquired by the French healthcare company UPSA in 2024. Unlike phytoestrogens, the active pollen extract does not act on estrogen receptors, and research suggests its mechanism of action may influence neurotransmitter-related pathways involved in thermoregulation, sleep, and mood.
- Brand names
- FEM Perimeno
- Other names
- FEM Perimeno with PeriCytoninFEM Perimeno with Pure CytoninUPSA FEM Perimeno
02
Targets
ER (Estrogen receptor)TACR3 (Neurokinin 3 Receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on FEM Perimeno.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FEM Perimeno.